In the field of nanomedicine a multitude of nanovectors have been developed for cancer
application. In this regard, a less exploited target is represented by connective tissue …

Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the
young population. Few options of systemic treatment are available once they become …

Background. Osteosarcoma, the most frequent osteogenic malignancy, has become a
serious public health challenge due to its high morbidity rates and metastatic potential …

Simple Summary Giant cell tumor of bone (GCTB) is an aggressive non-cancerous bone
tumor. Surgery remains the main treatment for GCTB. Denosumab has been approved for …

Osteosarcoma describes a tumor of mesenchymal origin with an annual incidence rate of
four to five people per million. Even though chemotherapy treatment has shown success in …

Simple Summary Jaw osteosarcoma (JO) differs from its long-bones counterpart in many
ways. The pathophysiology of this disease is still unknown, but the tumor microenvironment …

Simple Summary Giant cell tumor of bone (GCTB) is an intermediate bone neoplasm which
consists of several cell populations, including the neoplastic “stromal” cells. These cells …

Introduction Tumor progression is driven by intrinsic malignant behaviors caused by gene
mutation or epigenetic modulation, as well as crosstalk with the components in the tumor …

Curettage is recommended for the treatment of Campanacci stages 1–2 giant cell tumor of
bone (GCTB) in the extremities, pelvis, sacrum, and spine, without preoperative denosumab …

Objective To analyze the effectiveness of the long-term (> 12 months) administration of
anlotinib as a monotherapy or combined therapy in patients with advanced sarcomas …